Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.40), $0.08 better than the analyst estimate of ($1.48). Revenue for the quarter came in at $139.45 million versus the consensus estimate of $135.28 million.

GUIDANCE:

Ultragenyx Pharma sees FY2024 revenue of $530-550 million, versus the consensus of $537 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.